Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics stockholders approve 2024 equity plan increase of 5,097,095 shares

Neutral Impact 2 of 5 shareholder Written later

At its September 8, 2026 annual meeting, Artiva Biotherapeutics stockholders approved an amendment to the 2024 Equity Incentive Plan that adds 5,097,095 shares for issuance and counts shares issuable under pre-funded warrants in the annual automatic share reserve increase. Stockholders also re-elected two Class II directors and ratified KPMG LLP as the auditor for fiscal 2026, so shareholders face potential dilution from the expanded share reserve.

Key points

  • Plan amendment adds 5,097,095 shares of common stock for issuance; the board approved it on July 15, 2026
  • Brian Daniels, M.D. and Laura Stoppel, Ph.D. elected as Class II directors with terms through the 2029 annual meeting
  • Proposal 3 approved with 32,527,133 votes for and 6,816,989 against
  • KPMG LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2026

The filing

CompanyArtiva Biotherapeutics, Inc. (ARTV)
Form8-K, current report
Filed with the SECSep 11, 2026, 4:21 PM ET
Accession number0001193125-26-389308

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.